Tags

Type your tag names separated by a space and hit enter

Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Schizophr Res. 2009 Feb; 107(2-3):115-21.SR

Abstract

OBJECTIVE

This study examined the main metabolic side effects induced by antipsychotic treatment in a cohort of first episode drug-naïve subjects after the first year of treatment.

METHODS

A randomized, open-label, prospective clinical trial was conducted. Participants were 164 consecutive subjects included in a first episode program and never treated with antipsychotic medication. Patients were assigned to haloperidol, olanzapine or risperidone. The main outcome measures were changes at 1 year in fasting glucose parameters (glucose, insulin levels and insulin resistance index) and changes in fasting lipid parameters (total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol).

RESULTS

144 of the total sample were evaluated at 1 year. There was a statistically significant increase in the mean values of insulin levels, insulin resistance index, total cholesterol, LDL-cholesterol and triglycerides. No pathological values in fasting glucose plasma levels were found at baseline and there were no changes after 1 year. Weight gain was positively correlated with changes in insulin levels, insulin resistance index and triglyceride levels. We did not detect statistically significant differences between treatments in any of the parameters evaluated.

CONCLUSIONS

Fasting glycaemia and insulin concentrations at baseline do not support the hypothesis that schizophrenia is associated with an underlying abnormality in glucose metabolism. The changes in insulin and lipid parameters at 1 year seem to be related to the magnitude of weight gain. There were no significant differences between haloperidol, olanzapine and risperidone concerning metabolic adverse effects after the first year of treatment.

Authors+Show Affiliations

Department of Psychiatry, Marques de Valdecilla University Hospital, Avda. Valdecilla s/n, 39008, University of Cantabria, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18993033

Citation

Perez-Iglesias, Rocio, et al. "Glucose and Lipid Disturbances After 1 Year of Antipsychotic Treatment in a Drug-naïve Population." Schizophrenia Research, vol. 107, no. 2-3, 2009, pp. 115-21.
Perez-Iglesias R, Mata I, Pelayo-Teran JM, et al. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophr Res. 2009;107(2-3):115-21.
Perez-Iglesias, R., Mata, I., Pelayo-Teran, J. M., Amado, J. A., Garcia-Unzueta, M. T., Berja, A., Martinez-Garcia, O., Vazquez-Barquero, J. L., & Crespo-Facorro, B. (2009). Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophrenia Research, 107(2-3), 115-21. https://doi.org/10.1016/j.schres.2008.09.028
Perez-Iglesias R, et al. Glucose and Lipid Disturbances After 1 Year of Antipsychotic Treatment in a Drug-naïve Population. Schizophr Res. 2009;107(2-3):115-21. PubMed PMID: 18993033.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. AU - Perez-Iglesias,Rocio, AU - Mata,Ignacio, AU - Pelayo-Teran,Jose M, AU - Amado,Jose A, AU - Garcia-Unzueta,Maria T, AU - Berja,Ana, AU - Martinez-Garcia,Obdulia, AU - Vazquez-Barquero,Jose L, AU - Crespo-Facorro,Benedicto, Y1 - 2008/11/06/ PY - 2008/08/04/received PY - 2008/09/23/revised PY - 2008/09/30/accepted PY - 2008/11/11/pubmed PY - 2009/4/21/medline PY - 2008/11/11/entrez SP - 115 EP - 21 JF - Schizophrenia research JO - Schizophr. Res. VL - 107 IS - 2-3 N2 - OBJECTIVE: This study examined the main metabolic side effects induced by antipsychotic treatment in a cohort of first episode drug-naïve subjects after the first year of treatment. METHODS: A randomized, open-label, prospective clinical trial was conducted. Participants were 164 consecutive subjects included in a first episode program and never treated with antipsychotic medication. Patients were assigned to haloperidol, olanzapine or risperidone. The main outcome measures were changes at 1 year in fasting glucose parameters (glucose, insulin levels and insulin resistance index) and changes in fasting lipid parameters (total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol). RESULTS: 144 of the total sample were evaluated at 1 year. There was a statistically significant increase in the mean values of insulin levels, insulin resistance index, total cholesterol, LDL-cholesterol and triglycerides. No pathological values in fasting glucose plasma levels were found at baseline and there were no changes after 1 year. Weight gain was positively correlated with changes in insulin levels, insulin resistance index and triglyceride levels. We did not detect statistically significant differences between treatments in any of the parameters evaluated. CONCLUSIONS: Fasting glycaemia and insulin concentrations at baseline do not support the hypothesis that schizophrenia is associated with an underlying abnormality in glucose metabolism. The changes in insulin and lipid parameters at 1 year seem to be related to the magnitude of weight gain. There were no significant differences between haloperidol, olanzapine and risperidone concerning metabolic adverse effects after the first year of treatment. SN - 0920-9964 UR - https://www.unboundmedicine.com/medline/citation/18993033/Glucose_and_lipid_disturbances_after_1_year_of_antipsychotic_treatment_in_a_drug_naïve_population_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0920-9964(08)00461-1 DB - PRIME DP - Unbound Medicine ER -